New Pill Targets Cervical Cancer At Its Root

A new oral therapy, SHetA2, is being developed to combat cervical cancer by targeting the virus's cancer-causing proteins. This small molecule therapy works by disrupting the interaction between HPV proteins and human cells, allowing the body's natural defenses to eliminate the harmful viral components.

The therapy is specifically aimed at individuals who have developed precancerous cervical lesions. Clinical studies are ongoing to precisely define the patient population and the stages of the disease where SHetA2 will be most effective.

Developed collaboratively by the Stephenson Cancer Center and ICMR-NICPR, SHetA2 has been advanced to Emcure Pharmaceuticals for further large-scale human trials. These trials are expected to take approximately five years before the therapy potentially becomes available on the market.

While the final cost is undetermined, SHetA2 is projected to be substantially more affordable than many existing cancer treatments. Its oral administration may also reduce the need for frequent hospital visits, potentially offering a more convenient and cost-effective treatment option for patients.